What is Semax? The research and its FDA status

Quick answer Semax is a lab-made peptide built from a fragment of ACTH, a pituitary hormone, and most of its small studies come from Russia, where FDA says it is a registered drug. In July 2026 an FDA advisory committee reviewed it, and news reports say the committee recommended adding it to the list of ingredients pharmacies may compound, against the advice of FDA's own staff. Today nothing has changed in the United States: Semax is not FDA-approved and not on that list, so licensed pharmacies can't compound it. The thing to watch is a proposed rule from FDA, which hadn't appeared as of October 2026.

What is Semax?

FDA's briefing document describes Semax as an analog of a fragment of adrenocorticotropic hormone (ACTH), a hormone made by the pituitary gland, with the last three amino acids swapped for a proline-glycine-proline tail. That tail is thought to make the molecule more stable. Because it is a different molecule from ACTH, what is known about ACTH doesn't transfer to it.

FDA's briefing says Semax is a registered drug in Russia, available there as nasal drops. It is not approved in the United States, and FDA noted that the European, Japanese and international pharmacopoeias have no standard for it.

What the research measured

Most of the published work comes from Russian research groups, and the human studies were small.

• Rat studies from Moscow gave Semax through the nose after blood flow to part of the brain was cut off, and measured tissue damage.
• The human studies were small: 37 adults with head or face pain (uncontrolled), a stroke study with no placebo group described, and a brain-scan study in 24 healthy adults.
• FDA judged the evidence for cerebral ischemia, migraine and trigeminal neuralgia insufficient, and found human studies only of nasal use, none of injection.

In rats. A 2006 study cut off blood flow to one part of the brain, then gave Semax through the nose for six days. The authors reported a smaller area of damage and better results on a memory task (Romanova and colleagues, 2006). A 2011 pilot study reported less tissue damage under a different model of reduced blood flow to the brain (Stavchansky and colleagues, 2011). FDA's staff noted that studies like these tested one fixed amount, so they can't show how the response changes with the amount given.

In people with pain. FDA's briefing describes a 1996 Russian study (Koroleva and colleagues, 1996) of 37 adults with migraine or trigeminal neuralgia, a facial pain condition, who each received one nasal administration. FDA called it small, uncontrolled and open-label, and said it did not show the product worked for most people in it.

After stroke. A 1997 study compared 30 patients given Semax alongside standard care with 80 given standard care alone, in the first days after a stroke (Gusev and colleagues, 1997). We read only the English abstract, which doesn't describe a placebo group or blinding, so its results can't be taken at face value. FDA's staff didn't weigh studies like this without full English translations.

In healthy volunteers. A 2018 study gave 14 healthy adults Semax by nose spray and 10 a placebo, with brain scans before and after. It reported differences in the pattern of one brain network. It measured brain activity, not symptoms (Lebedeva and colleagues, 2018).

Several had no placebo group, and FDA could not tell which form, free base or salt, was used. Full citations are in the Sources list below.

Three things FDA's reviewers flagged

FDA's July 2026 briefing raised three specific concerns.

The first is bleeding. Rat studies and one meeting abstract described anti-clotting effects, and FDA said this raises concern about bleeding risk, particularly for people already at risk of bleeding or taking medicines that affect it.

The second is brain chemistry. In mice, Semax increased the dopamine release caused by amphetamine. FDA called this concerning, because increased dopamine activity in that brain region is also seen with drugs of abuse, and it found no studies of Semax's abuse potential.

The third is the spray itself. FDA had strong concerns about a compounded nasal spray because nothing described its container, closure or pump; the certificates of analysis it saw lacked tests for impurities, clumping and bacterial endotoxins.

Why licensed pharmacies can't compound it

Semax is not an FDA-approved drug and is not on FDA's 503A bulks list, so licensed pharmacies can't compound it; FDA removed it from its interim Category 2 on April 22, 2026 after the nominators withdrew their nominations, which FDA says is not a determination about the substance (how the categories work). In July 2026 FDA's reviewers proposed against adding it to the list, news reports (STAT, July 24, 2026) say the advisory committee voted to recommend adding it anyway, and only a final rule after notice-and-comment rulemaking would change that, with no proposed rule published as of October 6, 2026 (the vote and the rulemaking path).

Is this right for me?

Not now. No licensed pharmacy can compound Semax, so no provider can prescribe it through a lawful pharmacy, whatever your health history.

What you can do: if you want to know when availability changes, the sign-up at the end of this page carries nothing but that news. If what drew you here is focus, memory, headaches or stroke care, your own doctor can go through approved options. And pass on nasal sprays or injections sold as "research use only": FDA's own review flagged the spray's container and quality as open questions.

If FDA's rules ever change, an independent licensed provider in your state would still review your history and decide. The answer may be no.

How it works

1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
2. Hear from us only if it becomes available through a licensed provider. We write about availability and nothing else, and you can unsubscribe anytime.
3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If FDA's rules change, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is Semax legal in the United States? It is not FDA-approved and not on the 503A bulks list, so licensed pharmacies can't compound it. Questions about a particular seller are for a lawyer.

Is Semax just ACTH? No. It is built from a short fragment of ACTH with a different tail. It is a different molecule.

Did the FDA advisory committee approve Semax? No. An advisory committee can only recommend. FDA has to finish rulemaking first, and being on the bulks list would not make it an approved drug.

Why do the studies come mostly from Russia? It is a registered drug there. Some of that work is in Russian-language journals FDA couldn't weigh without full translations.

When could Semax become available? No one can give a date. A proposed rule in the Federal Register would be the first real change.

What this means for you

As of October 2026, licensed pharmacies can't legally compound Semax for patients: it isn't on FDA's 503A bulks list, and only FDA rulemaking changes that. If FDA lists it one day, the legal route would be a prescription from a licensed provider in your state, filled by a licensed pharmacy; compounded medications are not FDA-approved. Until then, products sold online as "research use only" aren't made for people.

The July 2026 FDA peptide vote, explained covers all seven peptides the committee reviewed and what has to happen next.

Safety information

FDA's safety page (content current as of April 22, 2026) says, word for word: "Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."

• Missing studies. FDA found no studies of how the body absorbs and clears Semax in people, and none of single or repeated exposure or of reproduction. The only cancer-related study it described, in mice, it called inadequately designed to assess cancer risk.
• Adverse-event reports. FDA's database held one report through December 2025, from a consumer who described lasting eye pain and burning after using Semax nasal drops she found online. Such reports can't show cause, and pharmacies compounding under 503A generally don't report to FDA.
• "Research use only" products. FDA's briefing says Semax nasal and injectable products are widely marketed in the United States through wellness clinics, concierge practices and online retailers, many without saying whether they are compounded; FDA's web search found no pharmacies marketing it. One online retailer sold it "for research purposes only." FDA has said in writing that a "research use only" label doesn't change its view when a seller's website shows the product is meant for people. Products sold online as "research use only" are a different, unregulated market that Everlon does not participate in and that carries additional dangers. What the label means.
• Had a reaction? Tell a doctor and report it to FDA's MedWatch.

If this is a medical emergency, call 911.

Sources

• Romanova GA, Silachev DN, Shakova FM, et al. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine. 2006;142(6):663-666. PMID: 17603664. PubMed, accessed 2026-10-06
• Stavchansky VV, Yuzhakov VV, Botsina AY, et al. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of Molecular Neuroscience. 2011;45(2):177-185. PMID: 20617398. PubMed, accessed 2026-10-06
• Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 1997;97(6):26-34 (in Russian, English abstract). PMID: 11517472. PubMed, accessed 2026-10-06
• Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine. 2018;165(5):653-656. PMID: 30225715. PubMed, accessed 2026-10-06
• FDA. FDA Briefing Document: Semax-related bulk drug substances (Semax free base and Semax acetate). Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov, accessed 2026-10-06
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories list), version updated April 22, 2026, archived copy; Semax removed from Category 2 because its nominations were withdrawn. web.archive.org, accessed 2026-10-06
• FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov, accessed 2026-10-06
• FDA. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act: Guidance for Industry. January 2025. fda.gov, accessed 2026-10-06
• FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Request for Comments. Federal Register. 2026;91:20465. FR Doc. 2026-07361, Docket FDA-2025-N-6895. April 16, 2026. federalregister.gov, accessed 2026-10-06
• 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
• FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
• STAT News. FDA advisory panel rejects compounding of one peptide, backs another. July 24, 2026 (news report of the committee votes). statnews.com, accessed 2026-10-06